Stock

AstraZeneca

AZN.L

Drug Manufacturers - General · Healthcare

Also trades as: AZN USD 172.57 (+2.45%)

Price

12,754.00 GBp

-226.00 (-1.74%)

Market Cap

£197.80B

Exchange

London Stock Exchange

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Data as of Oct 23, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality

Strong

25/30

Growth

Strong

15/20

Cash Flow

Exceptional

9/10

Stability

Good

6/10

Valuation

Strong

8/10

Ownership

Weak

2/15

Dividends

Good

3/5

68 of 100 counted points = Winston Score 68.

Track this stock — start free trial

Share count rising — dilution

+9.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.43B (2021) → 1.56B (2025)

§Winston Score History

The full picture

AstraZeneca is a large pharmaceutical company that discovers, makes, and sells prescription medicines. Its main products treat cancer, heart disease, diabetes, and respiratory conditions like asthma. Key drug brands include Tagrisso, Farxiga, and Symbicort, and its customers are hospitals, doctors, and patients across the world.

The company earns money by selling patented medicines directly to healthcare systems, insurers, and pharmacies. AstraZeneca operates globally, with major revenue coming from the United States, Europe, and China, and it generates over $45 billion in annual revenue. Its moat comes from a strong pipeline of patented drugs and heavy investment in research and development, but the biggest ongoing risk is patent expiration — when key drugs lose exclusivity, cheaper generic versions enter the market and can sharply reduce revenue.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+3.0% YoY

YoY Growth Rate

Slow revenue growth

Reported EPS Growth

-1.2% YoY

Quarterly reporting periods ended:

30 Jun 2025: $1.62

30 Jun 2026: $1.60

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS decreased year over year

R&D Spend

$14.2B/ year

↑ Rising (+19% vs prior year)

24.2% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

0.5%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$9.7B cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Heavy R&D investment

AstraZeneca is putting 24% of revenue into R&D and that number is rising. And they're generating enough cash to self-fund it.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

73.6%

Premium pricing power — 73.6% gross margin

Profit after running costs

Operating Margin

20.2%

Excellent — 20.2% operating margin

Return on the money invested

ROCE

16.8%

Strong — 16.8% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+6.9%

Slow sales growth (+6.9% YoY)

Profit growth

EPS YoY

+23.3%

Earnings growing fast (+23.3% YoY)

Healthy double-digit earnings growth — what compounders look like.

How steady the profit is

EPS Consistency

7/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

132%

Turns 132% of profit into real cash

Spare cash per sale

FCF Margin

13.8%

Converts sales into free cash efficiently (13.8%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.64

Moderate — manageable debt (0.64)

Covers its interest

Interest Cover

7.97x

Adequate interest coverage (8.0x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

19.0x

Fair value — P/E 19.0

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year

P/E vs Forward

+6.1

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (19.0 → 12.9)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

1.90%

Small dividend — 1.90% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record

Dividend Growth

+28.7%

Dividend growing fast (28.7% YoY)

Payout Ratio

47%

no trend

Pays out a modest share of profit and keeps the rest to reinvest. Room to keep paying through a weak year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial